Ignite Creation Date:
2024-05-06 @ 4:17 PM
Last Modification Date:
2024-10-26 @ 2:07 PM
Study NCT ID:
NCT04933227
Status:
TERMINATED
Last Update Posted:
2024-03-12
First Post:
2021-06-17
Brief Title:
A Study to Explore the Efficacy and Safety of Atezolizumab Plus Tiragolumab and Chemotherapy in 1st Line HER2 Negative Unresectable Recurrent or Metastatic Gastric Cancer or Adenocarcinoma of Gastroesophageal Junction GEJ
Sponsor:
Hoffmann-La Roche
Organization:
Hoffmann-La Roche
Key Dates - Follows AllAPIJSON File Order
Start Date:
2021-08-06
Start Date Type:
ACTUAL
Primary Completion Date:
2023-11-17
Primary Completion Date Type:
ACTUAL
Completion Date:
2023-11-17
Completion Date Type:
ACTUAL
First Submit Date:
2021-06-17
First Submit QC Date:
June 17 2021
Study First Post Date:
2021-06-21
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2024-03-07
Last Update Post Date:
2024-03-12
Last Update Post Date Type:
ACTUAL